Journal
EBIOMEDICINE
Volume 44, Issue -, Pages 419-430Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2019.05.035
Keywords
BET bromodomain inhibitor (BETi); Pancreatic cancer; PARP inhibitor (PARPi); DNA repair and damage; Patient-derived xenograft model; DNA double-strand break repair proteins
Funding
- National Institutes of Health (National Cancer Institute) [R01CA208272, R21CA205501]
- predoctoral training fellowship in Cell and Molecular Biology (CMB) T32 training grant (2017-2018)
- DoD OCRP pilot grant [W81XWH-15-1-0198]
- AstraZeneca
- ASCO
- Eli Lilly
- Novartis
- PUMA
Ask authors/readers for more resources
Background: DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1 increases levels of DNA damage, we evaluated the efficacy of JQ1 + the PARPi olaparib in preclinical models of pancreatic ductal adenocarcinoma (PDAC). We also addressed the mechanism by which JQ1 increased DNA damage. Methods: The effect of JQ1 + olaparib on in vivo tumor growth was assessed with patient derived xenograft (PDX) models of PDAC. Changes in protein expression were detected by immunohistochemistry and immunoblot. In vitro growth inhibition and mechanistic studies were done using alamarBlue, qRT-PCR, immunoblot, immunofluorescence, ChIP, and shRNA knockdown assays. Findings: Tumors exposed in vivo to JQ1 had higher levels of the DNA damage marker gamma H2AX than tumors exposed to vehicle only. Increases in gamma H2AX was concomitant with decreased expression of DNA repair proteins Ku80 and RAD51. JQI + olaparib inhibited the growth of PDX tumors greater than either drug alone. Mechanistically. ChIP assays demonstrated that JQ1 decreased the association of BRD4 and BRD2 with promoter loci of Ku80 and RAD51, and shRNA data showed that expression of Ku80 and RAD51 was BRD4- and BRD2-dependent in PDAC cell lines. Interpretation: The data are consistent with the hypothesis that JQ1 confers a repair deficient phenotype and the consequent accumulation of DNA damage sensitizes PDAC cells to PARPi. Combinations of BET inhibitors with PARPi may provide a novel strategy for treating PDAC. (C) 2019 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available